INS and metabolic dysfunction-associated steatotic liver disease: Recently, clinical trials have reported SGLT-2i had beneficial effects on NAFLD, as evidenced by the remarkably reduced ALT, AST, triglycerides, hepatic insulin sensitivity indices (Ranjbar et al., 2019; Kahl et al., 2020).